These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36763374)

  • 1. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
    Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
    Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
    Koh YX; Tan HJ; Liew YX; Syn N; Teo JY; Lee SY; Goh BKP; Goh GBB; Chan CY
    J Am Coll Surg; 2019 Nov; 229(5):467-478.e1. PubMed ID: 31398386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.
    Yang T; Hu LY; Li ZL; Liu K; Wu H; Xing H; Lau WY; Pawlik TM; Zeng YY; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Li C; Wang MD; Wu MC; Shen F
    J Gastrointest Surg; 2020 Feb; 24(2):320-329. PubMed ID: 30617773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis.
    Billeter AT; Müller PC; Albrecht T; Roessler S; Löffler M; Lemekhova A; Mehrabi A; Müller-Stich BP; Hoffmann K
    J Gastrointest Surg; 2021 May; 25(5):1193-1202. PubMed ID: 32378092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.
    Nachit M; Dioguardi Burgio M; Abyzov A; Garteiser P; Paradis V; Vilgrain V; Leclercq I; Van Beers BE
    Eur Radiol; 2024 Mar; 34(3):1461-1470. PubMed ID: 37658893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis.
    Young S; Sanghvi T; Rubin N; Hall D; Roller L; Charaf Y; Golzarian J
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):65-75. PubMed ID: 31686136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
    Ertle J; Dechêne A; Sowa JP; Penndorf V; Herzer K; Kaiser G; Schlaak JF; Gerken G; Syn WK; Canbay A
    Int J Cancer; 2011 May; 128(10):2436-43. PubMed ID: 21128245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
    Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
    Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
    Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
    Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
    Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
    J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
    Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
    J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.
    Shimomura Y; Takaki A; Wada N; Yasunaka T; Ikeda F; Maruyama T; Tamaki N; Uchida D; Onishi H; Kuwaki K; Nakamura S; Nouso K; Miyake Y; Koike K; Tomofuji T; Morita M; Yamamoto K; Okada H
    Intern Med; 2017; 56(3):243-251. PubMed ID: 28154266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.